Literature DB >> 8640345

Electrophysiological actions of felbamate on rat striatal neurones.

A Pisani1, A Stefani, A Siniscalchi, N B Mercuri, G Bernardi, P Calabresi.   

Abstract

1. We have investigated the effects of the anticonvulsant drug, felbamate (FBM), on striatal neurones, recorded in vitro by using both intracellular and extracellular conventional recordings in slices and whole-cell recordings in acutely isolated neurones. 2. FBM, at therapeutically relevant concentrations (30-300 microM) showed multiple mechanisms of action. Like other antiepileptic drugs, FBM (30-300 microM) showed a direct inhibitory action on current-evoked firing discharge of striatal neurones. A patch-clamp analysis of this effect revealed a dose-related reduction of voltage-dependent sodium (Na+) currents (10-100 microM), with a half inhibiton dose (IC50) value of 28 microM. 3. We also tested whether FBM affected corticostriatal glutamate transmission. In control medium (1.2 mM external magnesium), both extracellularly recorded field potentials and intracellularly recorded excitatory postsynaptic potentials (e.p.s.ps) evoked by cortical stimulation were no affected by bath application of 30-300 microM FBM. 4. When magnesium was removed from the perfusing solution, a procedure which reveals a N-methyl-D-aspartate (NMDA)-mediated component in the corticostriatal synaptic potential, FBM (30-300 microM) produced a dose-dependent reduction of the amplitude of both the field potential and the e.p.s.p. 5. FBM reduced the inward currents produced either by bath or by focal applications of 30 microM NMDA, finding consistent with the hypothesis that the observed reduction of the NMDA-mediated component of the synaptic potentials may be caused at postsynaptic level. 6. The reduction of the NMDA-mediated component of the synaptic transmission by FBM and its depressant effect on the voltage-dependent Na+ channels, may account for the antiepileptic action of this drug. Moreover, the pharmacological properties of FBM might render this drug interesting as a neuroprotectant agent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8640345      PMCID: PMC1908940          DOI: 10.1111/j.1476-5381.1995.tb16411.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  A neuropharmacological evaluation of felbamate as a novel anticonvulsant.

Authors:  H S White; H H Wolf; E A Swinyard; G A Skeen; R D Sofia
Journal:  Epilepsia       Date:  1992 May-Jun       Impact factor: 5.864

2.  Long-term and short-term plasticity in the CA1, CA3, and dentate regions of the rat hippocampal slice.

Authors:  B E Alger; T J Teyler
Journal:  Brain Res       Date:  1976-07-16       Impact factor: 3.252

3.  From the Food and Drug Administration.

Authors:  S L Nightingale
Journal:  JAMA       Date:  1994-10-05       Impact factor: 56.272

4.  Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats.

Authors:  E A Swinyard; R D Sofia; H J Kupferberg
Journal:  Epilepsia       Date:  1986 Jan-Feb       Impact factor: 5.864

5.  Protective effects of felbamate against hypoxia in the rat hippocampal slice.

Authors:  R A Wallis; K L Panizzon; M D Fairchild; C G Wasterlain
Journal:  Stroke       Date:  1992-04       Impact factor: 7.914

6.  An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels.

Authors:  H Cheung; D Kamp; E Harris
Journal:  Epilepsy Res       Date:  1992-11       Impact factor: 3.045

7.  Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain.

Authors:  R P Simon; J H Swan; T Griffiths; B S Meldrum
Journal:  Science       Date:  1984-11-16       Impact factor: 47.728

8.  Neuroprotective effect of felbamate after kainic acid-induced status epilepticus.

Authors:  A Chronopoulos; C Stafstrom; S Thurber; P Hyde; M Mikati; G L Holmes
Journal:  Epilepsia       Date:  1993 Mar-Apr       Impact factor: 5.864

9.  Post-receptor mechanisms underlying striatal long-term depression.

Authors:  P Calabresi; A Pisani; N B Mercuri; G Bernardi
Journal:  J Neurosci       Date:  1994-08       Impact factor: 6.167

10.  Felbamate, a novel antiepileptic drug, reverses N-methyl-D-aspartate/glycine-stimulated increases in intracellular Ca2+ concentration.

Authors:  L A Taylor; R D McQuade; M A Tice
Journal:  Eur J Pharmacol       Date:  1995-04-28       Impact factor: 4.432

View more
  6 in total

Review 1.  Neuroprotection as a Potential Therapeutic Perspective in Neurodegenerative Diseases: Focus on Antiepileptic Drugs.

Authors:  D Caccamo; L R Pisani; P Mazzocchetti; R Ientile; P Calabresi; F Pisani; C Costa
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

2.  An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons.

Authors:  P Calabresi; D Centonze; G A Marfia; A Pisani; G Bernardi
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 3.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Effects of anti-epileptic drugs on spreading depolarization-induced epileptiform activity in mouse hippocampal slices.

Authors:  Ching-Huei Lin; Shih-Pin Hsu; Ting-Chun Cheng; Chin-Wei Huang; Yao-Chang Chiang; I-Han Hsiao; Ming-Hsueh Lee; Mei-Lin Shen; Dong Chuan Wu; Ning Zhou
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

5.  Felbamate but not phenytoin or gabapentin reduces glutamate release by blocking presynaptic NMDA receptors in the entorhinal cortex.

Authors:  Jian Yang; Caroline Wetterstrand; Roland S G Jones
Journal:  Epilepsy Res       Date:  2007-11-05       Impact factor: 3.045

6.  Emerging drugs for partial-onset epilepsy: a review of brivaracetam.

Authors:  Lan Gao; Shuchuen Li
Journal:  Ther Clin Risk Manag       Date:  2016-05-04       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.